1AD 8.33% 2.6¢ adalta limited

Ann: Positive AD-214 Phase I extension study results, page-203

  1. rlj
    469 Posts.
    lightbulb Created with Sketch. 181
    Depends on the partnering route taken as to what the funds from the upfront are used for. The way I understand it:

    Option A = Out license to big pharma = sale of the AD214 asset with an upfront payment & contingent milestones = no further spend on AD214 for Adalta, can use the upfront to develop the pipeline of other drugs

    Option B = JV Partner with Private equity = AD214 into SPV, JV partner pays Adalta for a portion of equity in SPV = in phase II either the costs are shared with the JV partner or the JV partner pays 100% (depending on the deal and how much equity is given away) with hope of selling for more (to big pharma) at some point
    Last edited by rlj: 27/03/24
 
watchlist Created with Sketch. Add 1AD (ASX) to my watchlist
(20min delay)
Last
2.6¢
Change
0.002(8.33%)
Mkt cap ! $15.48M
Open High Low Value Volume
2.6¢ 2.6¢ 2.6¢ $8.093K 311.2K

Buyers (Bids)

No. Vol. Price($)
4 554539 2.2¢
 

Sellers (Offers)

Price($) Vol. No.
2.6¢ 400000 2
View Market Depth
Last trade - 11.36am 26/07/2024 (20 minute delay) ?
1AD (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.